Avidity Biosciences, Inc.
RNA
$26.57
-$1.53-5.45%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 10.90M | 10.12M | 10.60M | 10.87M | 9.56M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.90M | 10.12M | 10.60M | 10.87M | 9.56M |
| Cost of Revenue | 303.59M | 260.79M | 231.30M | 210.04M | 190.97M |
| Gross Profit | -292.70M | -250.67M | -220.70M | -199.17M | -181.41M |
| SG&A Expenses | 86.24M | 74.02M | 64.48M | 56.02M | 54.19M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 389.83M | 334.81M | 295.78M | 266.06M | 245.16M |
| Operating Income | -378.94M | -324.69M | -285.18M | -255.19M | -235.60M |
| Income Before Tax | -322.30M | -280.49M | -252.45M | -228.68M | -212.22M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -322.30 | -280.49 | -252.45 | -228.68 | -212.22 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -322.30M | -280.49M | -252.45M | -228.68M | -212.22M |
| EBIT | -378.94M | -324.69M | -285.18M | -255.19M | -235.60M |
| EBITDA | -376.16M | -322.04M | -282.67M | -252.84M | -233.50M |
| EPS Basic | -2.90 | -2.90 | -2.95 | -2.95 | -2.90 |
| Normalized Basic EPS | -1.81 | -1.81 | -1.85 | -1.84 | -1.81 |
| EPS Diluted | -2.90 | -2.90 | -2.95 | -2.95 | -2.90 |
| Normalized Diluted EPS | -1.81 | -1.81 | -1.85 | -1.84 | -1.81 |
| Average Basic Shares Outstanding | 446.01M | 393.57M | 344.29M | 308.75M | 291.97M |
| Average Diluted Shares Outstanding | 446.01M | 393.57M | 344.29M | 308.75M | 291.97M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
